Market Spotlight: Glaucoma
Market Spotlight: Glaucoma
$1,318.00
This Market Spotlight report covers the Glaucoma market, comprising key pipeline and marketed drugs, clinical trials, upcoming and regulatory events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Author: Informa Pharma Intelligence
Publisher: Datamonitor Healthcare
- Description
- Contents
Overview
This Market Spotlight report covers the Glaucoma market, comprising key marketed and pipeline drugs, clinical trials, upcoming and regulatory events, probability of success, patent information, recent events and analyst opinion, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts
Key Takeaways
- Datamonitor Healthcare estimates that in 2019, there were 99.7 million prevalent cases of glaucoma in adults aged 40 years and older worldwide, and forecasts that number to increase to 119.4 million prevalent cases by 2028.
- Africa is estimated to have the highest disease prevalence (4.79%), while Europe and Oceania have the lowest prevalence (2.93% and 2.97%, respectively).
- The majority of approved drugs in the glaucoma space target beta adrenergic receptors or the prostaglandin F receptor. Almost all of these approved drugs are administered via the topical route, with the remainder being intraocular/subretinal/subconjunctival or oral formulations.
- The majority of industry-sponsored drugs in active clinical development for glaucoma are in Phase II. While a small number of mid-to-late-stage drugs in the glaucoma space are exploring new targets, the established target prostaglandin F receptor continues to lead clinical development. The largest number of drugs in mid-to-late-stage development for glaucoma are administered via the intraocular/subretinal/subconjunctival route.
- High-impact upcoming events for drugs in the glaucoma space comprise topline Phase II trial results for GAL-101, topline Phase III trial results for Rocklatan and NCX 470, and an expected CHMP opinion for Rocklatan.
- The overall likelihood of approval of a Phase I glaucoma/ocular hypertension (ophthalmology) asset is 3.9%, and the average probability a drug advances from Phase III is 57.1%. Drugs, on average, take 9.0 years from Phase I to approval, compared to 8.8 years in the overall ophthalmology space.
- The distribution of clinical trials across Phase I–IV indicates that the majority of trials for glaucoma have been in the late phases of development, with 59% of trials in Phase III–IV, and 41% in Phase I–II.
- The US has a substantial lead in the number of glaucoma clinical trials globally. Germany leads the major European markets, while Japan has the top spot in Asia.
- Clinical trial activity in the glaucoma space is dominated by completed trials. Novartis has the highest number of completed clinical trials for glaucoma, with 156 trials.
- Novartis leads industry sponsors with by far the highest overall number of clinical trials for glaucoma, followed by Allergan
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
8 Subtypes
10 TREATMENT
10 Eye drops
10 Oral medications
10 Intraocular implant
12 EPIDEMIOLOGY
15 MARKETED DRUGS
22 PIPELINE DRUGS
29 RECENT EVENTS AND ANALYST OPINION
29 Nyxol for Glaucoma (November 7, 2019)
30 NCX 470 for Glaucoma (October 2, 2019)
31 Multiple Drugs/Devices for Glaucoma (June 25, 2019)
32 OTX-TP for Glaucoma (May 20, 2019)
33 Hydrus Microstent for Glaucoma (April 23, 2019)
35 CyPass Micro-Stent for Glaucoma (April 9, 2019)
36 Durysta for Glaucoma (January 7, 2019)
38 KEY UPCOMING EVENTS
39 KEY REGULATORY EVENTS
39 Allergan’s Ophthalmic Implant Technology Gets Nod For Durysta
39 Aerie Pharmaceuticals files MAA for Roclanda
39 New EU Approvals
40 PROBABILITY OF SUCCESS
41 LICENSING AND ASSET ACQUISITION DEALS
41 Novartis, Mundipharma In Taiwan Ophthalmology Deal
41 Glaukos Gets US Distribution Rights To Santen’s MicroShunt
42 REVENUE OPPORTUNITY
44 CLINICAL TRIAL LANDSCAPE
45 Sponsors by status
46 Sponsors by phase
48 BIBLIOGRAPHY
48 Prescription information
50 APPENDIX
LIST OF FIGURES
13 Figure 1: Trends in prevalent cases of glaucoma, 2019–28
22 Figure 2: Overview of pipeline drugs for glaucoma in the US
23 Figure 3: Pipeline drugs for glaucoma, by company
23 Figure 4: Pipeline drugs for glaucoma, by drug type
23 Figure 5: Pipeline drugs for glaucoma, by classification
30 Figure 6: Nyxol for Glaucoma (November 7, 2019): Phase II – ORION-1
31 Figure 7: NCX 470 for Glaucoma (October 2, 2019): Phase II – Dolomites
33 Figure 8: OTX-TP for Glaucoma (May 20, 2019): Phase III – vs. Placebo (First)
35 Figure 9: Hydrus Microstent for Glaucoma (April 23, 2019): COMPARE (US)
37 Figure 10: Durysta for Glaucoma (January 7, 2019): Phase III – 092
38 Figure 11: Key upcoming events in glaucoma
40 Figure 12: Probability of success in the glaucoma pipeline
44 Figure 13: Clinical trials in glaucoma
44 Figure 14: Top 10 drugs for clinical trials in glaucoma
45 Figure 15: Top 10 companies for clinical trials in glaucoma
45 Figure 16: Trial locations in glaucoma
46 Figure 17: Glaucoma trials status
47 Figure 18: Glaucoma trials sponsors, by phase
LIST OF TABLES
12 Table 1: Prevalent cases of glaucoma, 2019–28
14 Table 2: Prevalence proportions in glaucoma, 2019–28
16 Table 3: Marketed drugs for glaucoma
25 Table 4: Pipeline drugs for glaucoma in the US
29 Table 5: Nyxol for Glaucoma (November 7, 2019)
30 Table 6: NCX 470 for Glaucoma (October 2, 2019)
31 Table 7: Multiple Drugs/Devices for Glaucoma (June 25, 2019)
32 Table 8: OTX-TP for Glaucoma (May 20, 2019)
34 Table 9: Hydrus Microstent for Glaucoma (April 23, 2019)
35 Table 10: CyPass Micro-Stent for Glaucoma (April 9, 2019)
37 Table 11: Durysta for Glaucoma (January 7, 2019)
42 Table 12: Historical global sales, by drug ($m), 2014–18
43 Table 13: Forecasted global sales, by drug ($m), 2020–24
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Market Spotlight: Opioid-Induced Constipation 
Sign up to the